SPOCK1 Is a Novel Transforming Growth Factor-β–Induced Myoepithelial Marker That Enhances Invasion and Correlates with Poor Prognosis in Breast Cancer

Li-Ching Fan¹,², Yung-Ming Jeng¹,², Yueh-Tong Lu², Huang-Chun Lien¹,²*

¹ Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan, ² Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan

* huangchunliend@ntu.edu.tw

Abstract

In addition to contraction, myoepithelia have diverse paracrine effects, including a tumor suppression effect. However, certain myoepithelial markers have been shown to contribute to tumor progression. Transforming growth factor-β (TGF-β) is involved in the transdifferentiation of fibroblasts to contractile myofibroblasts. We investigated whether TGF-β can upregulate potential myoepithelial markers, which may have functional and clinicopathological significance in breast cancer. We found that TGF-β induced SPOCK1 expression in MCF10A, MCF12A, and M10 breast cells and demonstrated SPOCK1 as a novel myoepithelial marker that was immunolocalized within or beneath myoepithelia lining ductolobular units. A functional study showed that overexpression of SPOCK1 enhanced invasiveness in mammary immortalized and cancer cells. To further determine the biological significance of SPOCK1 in breast cancer, we investigated the expression of SPOCK1 in 478 invasive ductal carcinoma (IDC) cases through immunohistochemistry and correlated the expression with clinicopathological characteristics. SPOCK1 expression was significantly correlated with high pathological tumor size (P = 0.012), high histological grade (P = 0.013), the triple-negative phenotype (P = 0.022), and the basal-like phenotype (P = 0.026) and was correlated with a significantly poorer overall survival on univariate analysis (P = 0.001, log-rank test). Multivariate Cox regression analysis demonstrated that SPOCK1 expression maintained an independent poor prognostic factor of overall survival. Analysis of SPOCK1 expression on various non-IDC carcinoma subtypes showed an enrichment of SPOCK1 expression in metaplastic carcinoma, which is pathogenetically closely related to epithelial-mesenchymal transition (EMT). In conclusion, we identified SPOCK1 as a novel TGF-β–induced myoepithelial marker and further demonstrated that SPOCK1 enhanced invasion in breast cancer cells and correlated with poor prognosis in breast cancer clinical samples. The enrichment of SPOCK1 expression in metaplastic carcinoma and the correlation between SPOCK1 expression and high histological grading and basal-like phenotypes in IDC evidence an association between SPOCK1 and EMT.

OPEN ACCESS

Citation: Fan L-C, Jeng Y-M, Lu Y-T, Lien H-C (2016) SPOCK1 Is a Novel Transforming Growth Factor-β–Induced Myoepithelial Marker That Enhances Invasion and Correlates with Poor Prognosis in Breast Cancer. PLoS ONE 11(9): e0162933. doi:10.1371/journal.pone.0162933

Editor: Javier S Castresana, University of Navarra, SPAIN

Received: August 5, 2016
Accepted: August 30, 2016
Published: September 14, 2016

Copyright: © 2016 Fan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This study was supported by the National Science Council, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.
Introduction

The mammary epithelium is composed of 2 cell layers, the inner luminal cells and the outer myoepithelial cells (MECs). MECs have dual epithelial and smooth muscle phenotype. The function of MECs has traditionally been considered to be restricted to milk ejection during lactation, however, accumulating evidence has revealed that in addition to contraction, MECs have diverse paracrine effects related to epithelial differentiation and extracellular matrix formation [1]. Although a tumor suppressor role has been implicated in MECs [1,2], studies have suggested that MECs may contribute to the tumorigenesis of triple-negative breast tumors [1,3,4]. Moreover, a subset of breast tumors expressing MEC markers (e.g., CK5, caveolin 2, and secreted protein, acidic, cysteine-rich (SPARC)) are characterized by a particularly poor clinical outcome [5–7]. This indicates that certain MEC markers may have tumor progressive effects and thus correlate with poorer prognosis. Identification of such MEC markers may contribute to the understanding of MEC marker-related mammary pathogenesis.

Transforming growth factor-β (TGF-β) is a known mediator of tissue repair and wound healing [8,9]. In addition to its effect on extracellular matrix turnover, TGF-β is involved in the process of transdifferentiation of fibroblasts toward myofibroblasts during wound healing through the induction of a contractile phenotype and the upregulation of α-smooth muscle actin [10–12]. On the basis of the ability of TGF-β in the induction of contractile phenotype during fibroblast-myofibroblast transdifferentiation and on the dual epithelial and contractile phenotype in MECs, this study investigated whether TGF-β can upregulate potential MEC markers that can have functional and clinicopathological significance in breast cancer. Information derived would contribute to a better understanding of the role of TGF-β on breast cancer biology.

Materials and Methods

Cell culture

The MCF10A and MCF12A breast cell lines, obtained from The American Type Tissue Culture Collection, were maintained in DMEM/F12 medium (Life Technologies, Carlsbad, CA, USA) as previously described [13]. The H184B5F5/M10, MDA-MB231 and T47D cell lines were obtained from Bioresource Collection and Research Center (Hsinchu, Taiwan). The MDA-MB231 and T47D cell lines were maintained in DMEM medium supplemented with 10% FBS and the H184B5F5/M10 cell line was maintained in MEM medium supplemented with 10% FBS (Life Technologies). All cells were incubated at 37 °C in a humidified 5% CO₂ atmosphere. For TGF-β1 induction, cells were treated with recombinant human TGF-β1 (R&D Systems, Minneapolis, MN, USA) at a concentration of 5 ng/mL for the indicated time before analysis.

Microarray analysis

Total RNA for microarray analysis was prepared as previously described [14]. The microarray experiment and data analysis were done by Welgene Biotech (Taipei, Taiwan) using the Agilent Oligo Chip (Agilent SurePrint G3 Human V2 GE 8x60K Microarray, Agilent Technologies, USA). Microarrays were scanned by laser scanner and the microarray signal intensities were measured to identify gene expression differences and ratios of gene expression.

Plasmid construction and transient transfection

The SPOCK1-expressing plasmid, pCDH-SPOCK1, was constructed by subcloning the SPOCK1 cDNA (GeneScript, Piscataway, NJ, USA) into the pCDH-CMV-MCS-EF1-GFP
expression vector (System Biosciences, Mountain View, CA, USA). The plasmid was subsequently transfected into cells by using the Lipofectamine 3000 reagent (Invitrogen, Carlsbad, CA, USA).

Reverse transcription–polymerase chain reaction (RT–PCR) and Western blot

Total RNA was reverse transcribed into cDNA and RT–PCR using standard protocols [14]. The primer sets used were as follows: SPOCK1 forward primer, 5'-GTTTACTGCGCAAAGCCTCGC, SPOCK1 reverse primer, 5'-AGGTTCCGCAACTCCTTGCTG, internal control S26 ribosomal protein forward primer, 5'-CCGTGCCTCCAAGATGACCAAAG, and S26 reverse primer, 5'-GTTCGATCCCTTGCGGGCTTCAC. Whole-cell lysates were made in RIPA buffer and subjected to SDS-PAGE, transferred onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA), and incubated with primary antibodies SPOCK1 (1:1000, HPA007450, Sigma-Aldrich, St. Louis, MO, USA) and GAPDH (ab9485, Abcam, Cambridge, MA, USA). The western blots were then incubated with horseradish peroxidase–conjugated secondary antibodies and further detected using an enhanced chemiluminescence kit (T-Pro Biotechnology, Taipei, Taiwan).

In vitro invasion assay

The invasive capability of cells was examined using polycarbonate transwell filters containing 8-μm pores (Corning Coster, Cambridge, MA, USA). Cells (2 × 10^4) seeded in serum-free medium on the upper side of the chamber coated with Matrigel (BD Biosciences, Bedford, MA, USA). The cells were allowed to migrate toward the lower chamber containing media supplemented with 10% FBS. After 16-hours, cells on the lower side of the membrane were fixed, stained with crystal violet and then counted.

Cell proliferation assay

Cell proliferation was measured using a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Cells were counted and seeded in 96-well plates, and then incubated at 37°C in a humidified 5% CO2 atmosphere. Twenty microliters of MTT reagent (5 mg/ml, Sigma) was added to each well at the end of incubation, then 4 hours later the medium was discarded and dimethylsulfoxide (DMSO) was added to each well to dissolve the purple crystal. Then the absorbance at 570 nm was measured.

Tumor sample and immunohistochemistry

Four hundred seventy-eight archives of breast invasive ductal carcinoma (IDC) paraffin tissue blocks from the Department of Pathology of National University (1993–2001) were arrayed in a high-density tissue array by using a 1-mm-diameter punch instrument, and the follow-up data of these patients were collected and used for survival analysis. Depending on tumor size, 2 to 4 cores were collected from each tumor case. Additional eighty–one cases of non-IDC breast carcinoma subtypes tissue blocks, including 35 invasive lobular carcinomas, 7 micropapillary carcinomas, 10 mucinous carcinomas, 8 invasive papillary carcinomas, 4 neuroendocrine carcinomas, 2 tubular carcinomas and 15 metaplastic breast carcinomas, were included for the analysis in breast carcinoma subtypes. Sections from primary breast cancer tissues were stained through immunohistochemistry as previously described [13]. The slides were incubated with a rabbit polyclonal antibody against human SPOCK1 (1:200, HPA007450, Sigma-Aldrich) and incubated with polymer–HRP reagent (Dako Cytomation, Glostrup, Denmark). Unequivocal
staining in equal to or higher than 5% of tumour cells was considered positive. Negative control slides were processed without primary antibody and were included for each staining. The remaining antibodies used for determining potential TGF-β-induced MEC markers were POSTN (GTX100602, GeneTex, Inc., Irvine, CA, USA), CXCR7 (HPA049718, Sigma-Aldrich), IGFL2 (HPA059137, Sigma-Aldrich), PCDH9 (HPA015581, Sigma-Aldrich), PRRX2 (HPA026808, Sigma-Aldrich), FBN1 (HPA017759, Sigma-Aldrich), PLAT (HPA003412, Sigma-Aldrich), and NOV (HPA019684, Sigma-Aldrich). All slides were reviewed by 2 pathologists (HCL and YMJ). This study was approved by Institutional Review Board of National Taiwan University Hospital. Because the tumor blocks from the 478 IDC cases that were used in the survival analysis were collected before November 2003 and were used only for immunohistochemistry, the written informed consent requirements were waived based on the regulation of our Institutional Review Board. The consent for the tumor blocks from the 81 breast cancer subtypes cases were not obtained because all patient information was anonymised with all patient identifiers removed.

Survival analysis
Statistical analyses were conducted using SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL, USA). The chi-square test was performed to analyze the correlation between SPOCK1 expression and clinicopathological parameters. The cumulative overall survival was calculated using the Kaplan-Meier method, and the log-rank test was used to analyze differences in the survival times. Univariate and multivariate survival with calculation of hazard ratios (HR) were performed using the Cox regression model. Statistical significance was set as P < 0.05.

Results
Identification of SPOCK1 as a novel TGF-β–induced myoepithelial marker
To identify potential TGF-β–induced myoepithelial markers, we treated human mammary epithelial MCF10A cells with TGF-β. We initially focused on the top 30 TGF-β–upregulated genes (S1 Table). Of the 30 genes, we investigated protein expression of the genes for which antibodies suitable for immunohistochemistry of the gene products were available but for which information on the expression of the gene products, particularly regarding MEC, was not yet available (S1 Table). Among the 9 genes evaluated—namely POSTN, CXCR7, IGFL2, SPOCK1, PCDH9, PRRX2, FBN1, PLAT, and NOV—we found that SPOCK1 (SPARC/osteonectin, CWCV and kazal-like domains proteoglycan 1) was the only myoepithelial marker that was immunolocalized within or beneath the MECs (Fig 1A). The upregulation of SPOCK1 at RNA and protein levels by TGF-β were also observed in 2 other mammary epithelial cells, MCF12A and M10 cells, in addition to MCF10A cells (Fig 1B), which confirmed SPOCK1 as a novel TGF-β–induced myoepithelial marker.

SPOCK1 enhanced invasion in immortalized breast epithelial cell and breast cancer cells
To test the hypothesis that certain MEC markers may have tumor progressive effect and confer adverse prognosis in breast cancer, we characterized the functional role of SPOCK1. We overexpressed SPOCK1 through transient transfection in MCF10A cells and 2 breast cancer cell lines, T47D and MB231, and performed invasion assay. SPOCK1 expression at the RNA and protein levels were confirmed through RT–PCR and Western blotting, respectively (Fig 1C). Notably, overexpression of SPOCK1 in MCF10A cells significantly promoted the invasive
capabilities, compared with control cells. This observation was further confirmed in T47D and MB231 cells (Fig 1D). However, overexpression of SPOCK1 had no significant effects on cell proliferation (Fig 1D), indicating that the difference in invasion was not caused by proliferation. These results demonstrate a role for SPOCK1 in mammary cell invasion.

Clinicopathological significance of SPOCK1 expression in human breast cancer

To investigate the clinicopathological significance of SPOCK1 expression, we analyzed the association between SPOCK1 expression and clinicopathological parameters in 478 cases of IDC with available clinicopathological information (Table 1 and Fig 2A). In normal breast, SPOCK1 was expressed consistently within or beneath the MECs lining the ductolobular units and also in the smooth muscle vessel walls. Luminal cells, by contrast, showed negative
Table 1. Association of SPOCK1 expression with clinicopathological factors for 478 cases of IDC.

| Clinicopathological variables | SPOCK1 expression | Chi-square test |
|------------------------------|-------------------|-----------------|
|                             | Negative n (%) | Positive n (%) | Total * | χ² | P |
| Age (years)                  |                  |                |         |    |   |
| ≤50                          | 197 (80.4)       | 48 (19.6)      | 245     | -0.020 | 0.662 |
| >50                          | 191 (82.0)       | 42 (18.0)      | 233     |                |           |
| Pathological tumor size (cm) |                  |                |         |    |   |
| T1                           | 125 (89.3)       | 15 (10.7)      | 140     | 0.106 | 0.012* |
| T2                           | 215 (77.3)       | 63 (22.7)      | 278     |                |           |
| T3 and T4                    | 47 (79.7)        | 12 (20.3)      | 59      |                |           |
| Pathological lymph node status |                |                |         |    |   |
| Negative                     | 168 (82.4)       | 36 (17.6)      | 204     | 0.027 | 0.558 |
| Positive                     | 215 (80.2)       | 53 (19.8)      | 268     |                |           |
| Pathological tumor stage     |                  |                |         |    |   |
| I                            | 78 (87.6)        | 11 (12.4)      | 89      | 0.104 | 0.079 |
| II                           | 183 (82.1)       | 40 (17.9)      | 223     |                |           |
| III                          | 122 (76.3)       | 38 (23.8)      | 160     |                |           |
| SBR grade                    |                  |                |         |    |   |
| I                            | 118 (83.7)       | 23 (16.3)      | 141     | 0.105 | 0.013* |
| II                           | 189 (84.4)       | 35 (15.6)      | 224     |                |           |
| III                          | 81 (71.7)        | 32 (28.3)      | 113     |                |           |
| Estrogen receptor            |                  |                |         |    |   |
| Negative                     | 122 (73.5)       | 44 (26.5)      | 166     | -0.143 | 0.002* |
| Positive                     | 266 (85.3)       | 46 (14.7)      | 312     |                |           |
| Progesteron receptor         |                  |                |         |    |   |
| Negative                     | 135 (78.5)       | 37 (21.50)     | 172     | -0.051 | 0.261 |
| Positive                     | 253 (82.7)       | 53 (17.3)      | 306     |                |           |
| HER2b                        |                  |                |         |    |   |
| Negative                     | 316 (82.3)       | 68 (17.7)      | 384     | 0.058 | 0.205 |
| Positive                     | 72 (76.6)        | 22 (23.4)      | 94      |                |           |
| Positivity for triple negativityc |                 |                |         | 0.105 | 0.022* |
| Negative                     | 335 (82.9)       | 69 (17.1)      | 404     |                |           |
| Positive                     | 53 (71.6)        | 21 (28.4)      | 74      |                |           |
| Basal-like phenotype d       |                  |                |         |    |   |
| Negative                     | 377 (82.0)       | 83 (18.0)      | 460     | 0.102 | 0.026* |
| Positive                     | 11 (61.1)        | 7 (38.9)       | 18      |                |           |
| Adjuvant CT and/or HT        |                  |                |         | 0.068 | 0.152 |
| Negative                     | 24 (92.3)        | 2 (7.7)        | 26      |                |           |
| Positive                     | 344 (81.1)       | 80 (18.9)      | 424     |                |           |

SBR grade, Scarff–Bloom–Richardson grade; CT, chemotherapy; HR, hormone therapy

*Significance level was set at P < 0.05

Numbers do not always add up to 478 because of the lack of tumor excision and/or lymph node sampling in some cases.

HER2-positive: HER2: 3+/3+ (IHC) or 2+/3+ (IHC) and positive on HER2 FISH test. HER2-negative: HER2: 0–1+/3+ (IHC) or HER2: 2+/3+, but negative on HER-2/neu FISH test. A commercially available dual-color FISH kit for simultaneous evaluation of HER-2/neu gene and chromosome 17 copy number was used according to the manufacturer instructions (PathVysion™ HER-2 DNA Probe Kit, Vysis, Inc., Downers Grove, IL, USA).

Staining intensity: ER−, PR−, and HER2−.

Positivity for triple negativity: ER−, PR−, HER2−, and CK5/6+ (>10% tumor cells).

doi:10.1371/journal.pone.0162933.t001
staining. SPOCK1 expression was observed in 18.8% (90/478) of IDC specimens, and the expression was positively correlated with a high pathological tumor size ($P = 0.012$), a high histological grade ($P = 0.013$), the triple-negative phenotype (ER$^-$, PR$^-$, and HER2$^-$; $P = 0.022$), and the basal-like phenotype (ER$^-$, PR$^-$, HER2$^-$ and CK5/6$^+$; $P = 0.026$). To investigate whether SPOCK1 expression demonstrated any prognostic impact, we analyzed the association between SPOCK1 expression and overall survival in IDC cases with available overall survival data. In the Kaplan–Meier survival curve for overall survival, a statistically significant poorer prognosis was observed in the SPOCK1-positive patients compared with the SPOCK1-negative patients ($P = 0.001$, log-rank test; Fig 2B). A further multivariate Cox regression analysis demonstrated that SPOCK1 expression status maintained prognostic significance with respect to overall survival after adjustment, with a hazard ratio of 1.565 (95% CI = 1.045 to 2.343, $P = 0.030$; Table 2).

Expression of SPOCK1 in breast carcinoma subtypes

To determine the SPOCK1 expression status in non-IDC breast carcinoma subtypes, we performed immunohistochemistry for SPOCK1 in 81 breast carcinomas of different histological subtypes; representative figures are shown in Fig 3. Compared with the expression in 18.8% of
IDC cases, SPOCK1 expression was rarely observed in cases of invasive lobular carcinoma (2/35), micropapillary carcinoma (1/7), mucinous carcinoma (0/10), invasive papillary carcinoma (0/8), invasive neuroendocrine carcinoma (0/4), and tubular carcinoma (0/2) (Table 3). In sharp contrast to the aforementioned carcinoma subtypes, over half of the metaplastic breast carcinoma (MBC; 10/15, 66.7%) were strongly positive for SPOCK1 (Table 3). These 15 MBC cases included 4 cases in the original cohort and 11 additionally included cases because of the high expression of SPOCK1 in MBC (3/5) in the original cohort. In SPOCK1-positive biphasic MBC cases, staining was observed in both sarcomatous and carcinomatous components.

Discussion

SPOCK1, also known as testican-1, is a heparin/chondroitin-sulfate–bearing proteoglycan originally identified in human testicular seminal plasma [15–17]. It belongs to a matricellular protein family named SPARC. The SPARC family of proteins consists of SPARC (osteonectin), Hevin (SPARC-like protein 1), secreted modular calcium binding protein (SMOC) 1 and 2, testican-1, 2 and 3, and follistatin like protein 1 [18]. Members of the SPARC family share a follistatin-like domain and an extracellular calcium binding E-F hand motif, regulate extracellular matrix assembly and deposition, and modulate growth factor signaling pathways [18,19]. In the present study, we identified SPOCK1 as a novel MEC marker. Interestingly, expression profiling of purified normal human luminal and myoepithelial breast cells has identified SPARC (osteonectin) as a novel myoepithelial marker [7]. These results illustrated that members of the calcium-binding SPARC family play a role in the function of mammary MEC. Another gene expression profiling study using serial analysis of gene expression to analyze freshly isolated uncultured luminal epithelial and myoepithelial cells reported that a high fraction (43%) of the genes differentially expressed in MEC encode secreted or cell surface proteins [20]. These findings, together with the identification of the novel myoepithelial calcium-binding proteoglycan, SPOCK1, suggest that MECs are actively involved in autocrine–paracrine interactions [21]. Moreover, in the present study, we demonstrated that SPOCK1 enhanced invasion in breast cancer cells and correlated with poor prognosis in breast cancer clinical samples. Intriguingly, SPARC (osteonectin) has also been identified as an independent marker of poor prognosis in breast cancers [7,22]. Together, these observations substantiated the notion that dysregulation of certain MEC markers confers poor prognosis in breast cancers [5–7]. In addition, our finding is consistent with previous studies demonstrating that SPOCK1 plays a critical role in multiple cancers, including prostate cancer, glioblastoma, hepatocellular carcinoma, esophageal squamous cell carcinoma, lung carcinoma, and gall bladder carcinoma [16,19,23–26]. These studies confirm the role of SPOCK1 in the development and progression of multiple cancers and imply a potential role for SPOCK1 as a therapeutic target.
In this study, we identified SPOCK1 as a novel TGF-β–induced MEC marker. TGF-β is a multifunctional protein involving tissue repair, wound healing, and progressive fibrosis [9,27]. In addition to its effect on extracellular matrix turnover, TGF-β is known to affect cell phenotype, including the induction of contractile phenotype and the upregulation of α-smooth muscle actin (α-SMA) during fibroblast–myofibroblast transdifferentiation [12]. Importantly, α-SMA is the most abundant actin isoform in mammary MECs and the contractile activity of MECs requires the expression of α-SMA and appropriate cell–extracellular matrix interaction [1]. Thus, the identification of SPOCK1 as a TGF-β–induced MEC marker further
substantiates a role of TGF-β in the function of MEC. Moreover, although an oncogenic role of SPOCK1 has been demonstrated in multiple cancers, very little is known about the pathogenesis of SPOCK1 dysregulation. We demonstrated a novel role of TGF-β in the induction of the MEC marker, SPOCK1, and the finding may suggest that alteration of the TGF-β pathway may be a potential cause of SPOCK1 dysregulation conferring poor prognosis in breast cancer. Moreover, the upregulation of SPOCK1 was observed in lung cancer cell A549 treated with TGF-β [25]. Although SPOCK1 was shown to be a CHD1L-upregulated gene underlying CHD1L-induced hepatocarcinogenesis [16,28], CDH1 expression was not altered in SPOCK1-expressing human breast cells induced by TGF-β (data not shown), suggesting that alteration of CDH1 is not involved in SPOCK1 expression in the breast.

In this study, we investigated the in situ expression patterns of the MEC marker, SPOCK1, in 478 IDC cases, as well as in 81 non-IDC histological carcinoma subtypes. We found expression of SPOCK1 in 18.8% of IDC cases, and the expression was significantly correlated with a high histological grade, the triple-negative phenotype, and the basal-like phenotype. Consistent with the association between SPOCK1 expression and such aggressive phenotypes, we have shown a significant correlation between SPOCK1 expression and poorer overall survival in our breast cancer cohort. The expression of SPOCK1 in up to 66.7% of MBC but rarely in other subtypes of breast carcinoma is remarkable. MBC, typically characterized by the coexistence of carcinomaous and sarcomatous components, has been shown to consistently harbor basal/myoepithelial phenotype and may represent morphological spectrum of basal-like and myoepithelial breast carcinomas [28–30]. Accumulating evidence indicates the critical role of epithelial–mesenchymal transition (EMT) in the pathogenesis of MBC [22,28,31,32]. Intriguingly, SPOCK1 expression has been shown to induce EMT in multiple cancer cell lines, including gall bladder, lung, and esophagus, and has been demonstrated to confer resistance to HER2 target therapy in gastric cancer cell line through EMT [24–26,33]. Thus, the enrichment of SPOCK1 expression in MBC and the correlation between SPOCK1 expression and triple-negative or basal-like IDC that have been shown to preferentially express EMT markers [34] provide in vivo evidence for an association between SPOCK1 and the EMT.

In conclusion, we identified SPOCK1 as a novel TGF-β–induced MEC marker and further demonstrated that SPOCK1 enhanced invasion in breast cancer cells and correlated with poor prognosis in breast cancer clinical samples. Our finding supports the role of certain myoepithelial markers in tumor progression and suggested that the alteration of the TGF-β pathway may be a potential cause of SPOCK1 dysregulation, conferring poor prognosis in breast cancer. The enrichment of SPOCK1 expression in MBC and the correlation between SPOCK1 expression and high histological grading and basal-like phenotypes in IDC evidence an association between SPOCK1 and the EMT.

### Table 3. SPOCK1 protein expression in non-IDC breast carcinoma subtypes.

| Carcinoma subtypes                  | Positive | Negative | Total |
|-------------------------------------|----------|----------|-------|
|                                     | n (%)    | n (%)    | n (%) |
| Invasive lobular carcinoma          | 2 (5.7)  | 34 (94.3)| 35 (100) |
| Mucinous carcinoma                  | 0 (0)    | 10 (100)| 10 (100) |
| Papillary carcinoma                 | 0 (0)    | 8 (100)| 8 (100) |
| Micropapillary carcinoma            | 1 (14.2)| 6 (85.8)| 7 (100) |
| Tubular carcinoma                   | 0 (0)    | 2 (100)| 2 (100) |
| Neuroendocrine carcinoma            | 0 (0)    | 4 (100)| 4 (100) |
| Metaplastic carcinoma               | 10 (66.7)| 5 (33.3)| 15 (100) |

doi:10.1371/journal.pone.0162933.t003

SPOCK1 as a TGF-β–Induced Myoepithelial Marker Correlates with Poor Prognosis in Breast Cancer

PLOS ONE | DOI:10.1371/journal.pone.0162933 September 14, 2016 10 / 13
Supporting Information

S1 Table. Top 30 TGF-β-upregulated genes in MCF10A cells.

Author Contributions

Conceptualization: HCL.
Data curation: HCL.
Formal analysis: HCL LCF YMJ.
Funding acquisition: HCL.
Investigation: HCL LCF YTL.
Methodology: HCL LCF.
Project administration: HCL.
Resources: HCL LCF YMJ.
Supervision: HCL.
Validation: HCL LCF YMJ.
Writing – original draft: HCL.
Writing – review & editing: HCL LCF YMJ.

References

1. Moumen M, Chiche A, Cagnet S, Petit V, Raymond K, Faraldo MM, et al. The mammary myoepithelial cell. The International Journal of Developmental Biology. 2011; 55: 763–771. PMID: 21948739. doi: 10.1387/ijdb.113395mm
2. Pandey PR, Saidou J, Watabe K. Role of myoepithelial cells in breast tumor progression. Frontiers in Bioscience. 2010; 15: 226–236. PMID: 20036817.
3. Bouras T, Pai B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR, et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell. 2008; 3: 429–441. PMID: 18940734. doi: 10.1016/j.stem.2008.08.001
4. Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedic M, et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell. 2011; 8: 149–163. PMID: 21295272. doi: 10.1016/j.stem.2010.12.007
5. Lachapelle J, Foulkes WD. Triple-negative and basal-like breast cancer: implications for oncologists. Current Oncology. 2011; 18: 161–164. PMID: 21874112.
6. Savage K, Leung S, Todd SK, Brown LA, Jones RL, Robertson D, et al. Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat. 2008; 110: 245–256. PMID: 17912630.
7. Jones C, Mackay A, Grigoriades A, Cossu A, Reis-Filho JS, Fulford L, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res. 2004; 64: 3037–3045. PMID: 15126339.
8. Midgley AC, Rogers M, Hallett MB, Clayton A, Bowen T, Phillips AO, et al. Transforming growth factor-β1 (TGF-β1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts. J Biol Chem. 2013; 288: 14824–14838. PMID: 23589287. doi: 10.1074/jbc.M113.451336
9. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994; 331: 1286–1292. PMID: 7835686.
10. Dugina V, Fortao L, Chaponnier C, Vasiliev J, Gabbiani G. Focal adhesion features during myofibroblastic differentiation are controlled by intracellular and extracellular factors. Journal of Cell Science. 2001; 114: 3285–3296. PMID: 11591817.
SPOCK1 as a TGF-β–Induced Myoepithelial Marker Correlates with Poor Prognosis in Breast Cancer

11. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003; 200: 500–503. PMID: 12845617.

12. Evans RA, Tian YC, Steadman R, Phillips AO. TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Experimental Cell Research. 2003; 282: 90–100. PMID: 12531695.

13. Lien HC, Lee YH, Jeng YM, Lin CH, Lu YS, Yao YT. Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance. Histopathology. 2014; 65: 328–339. PMID: 24527698. doi: 10.1111/his.12390

14. Huang FJ, Chen YL, Chang CN, Yuan RH, Jeng YM. Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion. Carcinogenesis. 2012; 33: 1142–1148. PMID: 22436613. doi: 10.1093/carcin/bgs131

15. Alliel PM, Perin JP, Jolles P, Bonnet FJ. Testican, a multidomain testicular proteoglycan resembling modulators of cell social behaviour. Eur J Biochem. 1993; 214: 347–350. PMID: 8389704.

16. Li Y, Chen L, Chan TH, Liu M, Kong KL, Qiu JL, et al. SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice. Gastroenterology. 2013; 144: 179–191. PMID: 23022495. doi: 10.1053/j.gastro.2012.09.042

17. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest. 2001; 107: 1049–1054. PMID: 11342565.

18. Bradshaw AD. Diverse biological functions of the SPARC family of proteins. The International Journal of Biochemistry & Cell biology. 2012; 44: 480–488. PMID: 22249026.

19. Yang C, Fischer-Keso R, Schlechter T, Strobel P, Marx A, Hofmann I. Plakophilin 1-deficient cells upregulate SPOCK1: implications for prostate cancer progression. Tumour Biology. 2015; 36: 9567–9577. PMID: 26138584. doi: 10.1007/s13277-015-3628-3

20. Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 2001; 61: 5697–5702. PMID: 11479200.

21. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation. 2002; 70: 537–546. PMID: 12492495.

22. Lien HC, Hsiao YH, Lin YS, Yao YT, Juan HF, Kuo WH, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene. 2007; 26: 7859–7871. PMID: 17603561.

23. Colin C, Baeza N, Bartoli C, Fina F, Eudes N, Nanni I, et al. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene. 2006; 25: 2818–2826. PMID: 16314830.

24. Song X, Pan P, Liu J, Wang Y, Li D, He J, et al. Up-regulation of SPOCK1 induces epithelial-mesenchymal transition and promotes migration and invasion in esophageal squamous cell carcinoma. Journal of Molecular Histology. 2015; 46: 347–356. PMID: 26077618. doi: 10.1007/s10735-015-9627-2

25. Miao L, Wang Y, Xia H, Yao C, Cai H, Song Y. SPOCK1 is a novel transforming growth factor-beta target gene that regulates lung cancer cell epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2013; 440: 792–797. PMID: 24134845. doi: 10.1016/j.bbrc.2013.10.024

26. Shu YJ, Weng H, Ye YY, Hu YP, Bao RF, Cao Y, et al. SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K/AKT pathway. Molecular Cancer. 2015; 14: 12. PMID: 25623055. doi: 10.1186/s12943-014-0276-y

27. Eddy AA. Progression in chronic kidney disease. Advances in Chronic Kidney Disease. 2005; 12: 353–365. PMID: 16198274.

28. Schwartz TL, Mogal H, Papageorgiou C, Veerapong J, Hsueh EC. Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies. Experimental Hematology & Oncology. 2013; 2: 31. PMID: 24499560.

29. Reis-Filho JS, Milanese F, Steele D, Savage K, Simpson PT, Nesland JM, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006; 49: 10–21. PMID: 16842242.

30. Carter MR, Hornick JL, Lester S, Fletcher CD. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol. 2006; 30: 300–309. PMID: 16538049.

31. Castilla MA, Diaz-Martín J, Carrio D, Romero-Perez L, Lopez-Garcia MA, Vieites B, et al. MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One. 2012; 7: e47709. PMID: 23112837. doi: 10.1371/journal.pone.0047709

32. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal
transition and stem cell characteristics. Cancer Res. 2009; 69: 4116–4124. PMID: 19435916. doi: 10.1158/0008-5472.CAN-08-3441

33. Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, et al. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer. Oncogene. 2014; 33: 3334–3341. PMID: 23873022. doi: 10.1038/onc.2013.285

34. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008; 68: 989–997. PMID: 18281472. doi: 10.1158/0008-5472.CAN-07-2017